Edition:
India

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

4.61USD
2:29am IST
Change (% chg)

$-0.09 (-1.91%)
Prev Close
$4.70
Open
$4.71
Day's High
$4.87
Day's Low
$4.59
Volume
101,718
Avg. Vol
509,646
52-wk High
$6.55
52-wk Low
$1.17

Chart for

About

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $244.81
Shares Outstanding(Mil.): 42.58
Dividend: --
Yield (%): --

Financials

BRIEF-‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6

* ‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​ Source text: [http://bit.ly/2A4glhH] Further company coverage:

17 Nov 2017

BRIEF-Endocyte Q3 loss per share $0.55

* Q3 loss per share $0.55 Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Endocyte Inc files for mixed shelf of upto $150 million

* Endocyte Inc says in addition, selling stockholders may offer and sell, up to 5.3 million shares of co's common stock‍​ Source text: (http://bit.ly/2i7ELz2) Further company coverage:

13 Oct 2017

BRIEF-Peter Dodwell reports 7.1 pct passive stake in Endocyte Inc

* Peter Dodwell reports 7.1 percent passive stake in Endocyte Inc ‍​as of September 29 - SEC filing Source text : (http://bit.ly/2gyKxWH) Further company coverage:

13 Oct 2017

BRIEF-Endocyte announces worldwide license of its radioligand therapy

* Endocyte announces exclusive worldwide license of phase 3 ready PSMA-targeted radioligand therapy for development in prostate cancer

02 Oct 2017

BRIEF-Endocyte says ABX GmbH eligible for milestones of up to $160 mln under license agreement

* Endocyte Inc - ‍ABX is eligible for regulatory and commercial milestones of up to $160 million, and tiered royalties beginning in mid-teens​

02 Oct 2017

BRIEF-Endocyte Q2 loss per share $0.28

* Endocyte reports second quarter financial results and provides clinical and pipeline update

09 Aug 2017

Competitors

Earnings vs. Estimates